Neumora Therapeutics Inc [NMRA] stock is trading at $1.91, up 10.40%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NMRA shares have gain 27.33% over the last week, with a monthly amount glided 17.90%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neumora Therapeutics Inc [NASDAQ: NMRA] stock has seen the most recent analyst activity on September 16, 2025, when JP Morgan downgraded its rating to a Underweight. Previously, BofA Securities downgraded its rating to Underperform on April 02, 2025, and kept the price target unchanged to $1. On March 10, 2025, downgrade downgraded it’s rating to Mkt Perform. Stifel downgraded its rating to a Hold and decreased its price target to $2 on March 07, 2025. Guggenheim downgraded its rating to a Neutral. RBC Capital Mkts downgraded its rating to Sector Perform for this stock on January 02, 2025, and downed its price target to $4. In a note dated November 05, 2024, JP Morgan downgraded a Neutral rating on this stock and revised its target price from $18 to $15.
Neumora Therapeutics Inc [NMRA] stock has fluctuated between $0.61 and $17.19 over the past year. Currently, Wall Street analysts expect the stock to reach $12.25 within the next 12 months. Neumora Therapeutics Inc [NASDAQ: NMRA] shares were valued at $1.91 at the most recent close of the market. An investor can expect a potential return of 541.36% based on the average NMRA price forecast.
Analyzing the NMRA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.13, Equity is -0.99 and Total Capital is -1.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7967 points at the first support level, and at 1.6833 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9667, and for the 2nd resistance point, it is at 2.0233.
Ratios To Look Out For
For context, Neumora Therapeutics Inc’s Current Ratio is 10.54. In addition, the Quick Ratio stands at 10.54 and the Cash Ratio stands at 5.89.
Transactions by insiders
Recent insider trading involved Henry Gosebruch, Officer, that happened on Mar 12 ’25 when 15000.0 shares were purchased. BERNS PAUL L completed a deal on Feb 18 ’25 to sell 13871.0 shares. Meanwhile, Milligan Michael Lee sold 1978.0 shares on Feb 18 ’25.
